Table 3.

Meta-analyses evaluating the COVID-19 Vaccine Effectiveness among immunocompromised patients (4 studies*).

	Studies Included (n)	Immunocompromised patients (n)	Pooled Diagnostic Odds Ratio [DOR] (95% CI)	I2 test for heterogeneity	Vaccine Effectiveness* (95%CI)
All studies evaluating vaccinated immunocompromised patients (two doses) and symptomatic COVID-19	4	42,821	0.296 (0.108, 0.811)	0%	70.4% (18.9%, 89.2%)

CI=Confidence Interval.

*Vaccine Effectiveness was estimated as 100% x (1-DOR).

[Chodick 2021; Havlin 2021; Khan 2021; Tenforde 2021*]

*We have opted to include in our meta-analysis Tenforde 2021 CID [50] because in Tenforde 2021 MMWR study [67] there are no raw numbers to perform the vaccine effectiveness for immunocompromised patients.